M3 USA has acquired Wake Research

M3 USA, a group company of M3, Inc. —a global leader in healthcare marketing, clinical trials, market research and physician recruitment services — has acquired Wake Research Associates, a clinical research site network.

• The acquisition strengthens M3’s market position as a leading provider of clinical research services globally, and marks the company’s entry into the clinical trial business in the United States.
• Wake Research is one of the largest independent Phase I-IV clinical trial site service companies in North America, with a proprietary clinical database of 1 million patients across its integrated network of 12 research sites
• M3, Inc. is a publicly traded company on the Tokyo Stock Exchange with subsidiaries across the globe and more than 2.5 million physician members worldwide via its physician websites
• M3 USA will immediately benefit from the addition of Wake’s industry leading capabilities, including centralized patient recruitment and retention, companywide QA/QC and in-house training programs, and robust marketing/advertising services

About M3 USA

M3 USA is a subsidiary of M3, Inc., a publicly traded company in the Tokyo Stock Exchange with subsidiaries in major markets including USA, France, UK, Japan, South Korea, and China. M3 was founded in 2000 with the goal of changing the world of medicine through full use of the power of the internet. M3 USA Group provides services to the healthcare and life sciences industry, including market research, medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services.

About Wake Research

Wake Research is an organization of unified investigational sites working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device, pharmaceutical industry and clinical research organizations. Based in the Research Triangle Park area of Raleigh, North Carolina, Wake Research is fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications, leveraging a proprietary clinical database of nearly 1 million patients across its network.